Peptides with HUGE Cardiovascular Impact!

**\*JOIN THE PHYSIONIC INSIDERS \[PREMIUM CONTENT]\***Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 **\*HEALTH AUTONOMY \[COURSE]\***Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy**\*JOIN THE COMMUNITY\***Join my Community \[It’s Free!]: https://bit.ly/PhysionicCommunity2**\*EMAIL LIST\***1-2 Weekly Email of Value \[It’s Free!]: http://bit.ly/2AXIzK6**\*HIRE ME FOR CONSULTING:\*** Consulting: https://bit.ly/3dmUl2H Created with Biorender0:00 - Introduction1:18 - Peptides on Cardiovascular Disease3:09 - Peptides on Reversing Arterial Plaque6:58 - There is hope...References \[Funding/Conflicts are provided in the free article (found in the email list and Physionic Community Article Library)] \[Study 1018] Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016. doi:10.1056/NEJMoa1607141. \[Study 1019] Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019. doi:10.1016/S0140-6736(19)31149-3. \[Study 1020] Gerstein HC, et al. The effect of dulaglutide on stroke: an exploratory analysis of REWIND. Lancet Diabetes Endocrinol. 2020. doi:10.1016/S2213-8587(19)30423-1. \[Study 1021] Hernandez AF, et al. Albiglutide and cardiovascular outcomes in type 2 diabetes and cardiovascular disease. Lancet. 2018. doi:10.1016/S0140-6736(18)32261-X. \[Study 1022] Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. doi:10.1056/NEJMoa2307563. \[Study 1023] McGuire DK, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025. doi:10.1056/NEJMoa2501006. \[Study 1024] Gitto M, et al. GLP-1 receptor agonists and coronary plaque regression after acute coronary syndromes. Acta Diabetol. 2026. doi:10.1007/s00592-025-02606-z. \[Study 1025] Kataoka Y, et al. GLP-1 analogues and delipidation of coronary atheroma. Atheroscler Plus. 2024. doi:10.1016/j.athplu.2024.03.001. \[Study 1026] Heinsen LJ, et al. Liraglutide treatment and progression of coronary artery fibrous plaque. BMC Cardiovasc Disord. 2023. doi:10.1186/s12872-023-03228-5. \[Study 1027] Zhang J, et al. Exenatide versus insulin and carotid intima-media thickness in type 2 diabetes. Cardiovasc Diabetol. 2020. doi:10.1186/s12933-020-01014-7. \[Study 1028] Rizzo M, et al. Liraglutide decreases carotid intima-media thickness in type 2 diabetes. Cardiovasc Diabetol. 2014. doi:10.1186/1475-2840-13-49. \[Study 1029] Rizzo M, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness. Cardiovasc Diabetol. 2016. doi:10.1186/s12933-016-0480-8. \[Study 1030] Patti AM, et al. Semaglutide and subclinical atherosclerosis in type 2 diabetes. Biomedicines. 2023. doi:10.3390/biomedicines11051362. \[Study 1031] Sun L, et al. Liraglutide and atherosclerosis in impaired glucose tolerance. Exp Ther Med. 2023. doi:10.3892/etm.2023.11948. \[Study 997] Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both. N Engl J Med. 2021. doi:10.1056/NEJMoa2028198. Please use the following link to submit your critique: https://bit.ly/PhysionicCritiqueDisclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.